Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2006-07-07
2010-12-07
Bunner, Bridget E (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C530S345000, C530S350000, C530S402000, C514S012200
Reexamination Certificate
active
07847062
ABSTRACT:
The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
REFERENCES:
patent: 5235041 (1993-08-01), Cappello et al.
patent: 5514581 (1996-05-01), Ferrari et al.
patent: 5545620 (1996-08-01), Wahl et al.
patent: 5641648 (1997-06-01), Ferrari et al.
patent: 5770697 (1998-06-01), Ferrari et al.
patent: 5792742 (1998-08-01), Gold et al.
patent: 6018030 (2000-01-01), Ferrari et al.
patent: 6207446 (2001-03-01), Szostak et al.
patent: 6214553 (2001-04-01), Szostak et al.
patent: 6258558 (2001-07-01), Szostak et al.
patent: 6261804 (2001-07-01), Szostak et al.
patent: 6281344 (2001-08-01), Szostak et al.
patent: 6383775 (2002-05-01), Duff et al.
patent: 6462189 (2002-10-01), Koide
patent: 6518018 (2003-02-01), Szostak et al.
patent: 6524583 (2003-02-01), Thorpe et al.
patent: 6559126 (2003-05-01), Tournaire et al.
patent: 6660492 (2003-12-01), Bode et al.
patent: 6818418 (2004-11-01), Lipovsek
patent: 7115396 (2006-10-01), Lipovsek et al.
patent: 2002/0019517 (2002-02-01), Koide
patent: 2002/0061307 (2002-05-01), Whitlow et al.
patent: 2003/0104520 (2003-06-01), Ellington et al.
patent: 2003/0170753 (2003-09-01), Koide
patent: 2005/0255548 (2005-11-01), Lipovsek
patent: WO-98/12226 (1998-03-01), None
patent: WO-98/31700 (1998-07-01), None
patent: WO-98/56915 (1998-12-01), None
patent: WO-99/51773 (1999-10-01), None
patent: WO-00/34784 (2000-06-01), None
patent: WO-01/64942 (2001-09-01), None
patent: WO-02/04523 (2002-01-01), None
patent: WO-02/32925 (2002-04-01), None
patent: WO-03/022858 (2003-03-01), None
patent: WO-2008/097497 (2008-08-01), None
patent: WO-2009/025806 (2009-02-01), None
patent: WO-2009/073115 (2009-06-01), None
Wells (1990) Biochemistry 29(37): 8509-8517.
Ngo et al (1994) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-440 and 492-495 only.
Bork (2000) Genome Research 10:398.
Skolnick et al (2000) Trends in Biotech. 18(1): 34.
Doerks et al (1998) Trends in Genetics 14(6): 248.
Smith et al (1997) Nature Biotechnology 15:1222.
Brenner (1999) Trends in Genetics 15(4): 132.
Bork et al (1996) Trends in Genetics 12(10): 425.
Choy et al (2002. Rheumatology. 41: 1133-1137).
Muyldermans (2001. Reviews in Molecular Biology 74: 277-302).
Maeda et al (2001. Advanced Drug Delivery Reviews. 46: 169-185).
Yang et al (Oct. 2003. Protein Engineering. 16(10): 761-770).
Zdanov, A., et al., “Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-Åresolution,” PNAS, 91:6421-6427 (1994).
Caliceti, P., et al., “Pharmacokinetic and biodistribution properties of poly(ethylene glycol)—protein conjugates,”Advanced Drug Delivery Reviews, 55:1261-1277 (2003).
Matsushima et al. Modification ofE. coliAsparaginase with 2,4-Bis(O-Methoxypolyethylene Glycol) -6-Chloro-S-Triazine (Activated PEG2); Disappearance of Binding Ability Towards Anti-Serum and Retention of Enzymic Activity. Chemistry Letters, p. 773-776 (1990).
Posey et al. A Phase I Trial of an Anti-KDR (VEGFR2) Chimeric Antibody in Patients with Liver Metastases in Colorectal Cancer (CRC). 2002 American Society of Clinical Oncology—Slides from the annual meeting (May 18-21).
Shibuya, M. “Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E,”Cancer Sci., 94(9):751-756 (2003).
Apte et al., Anchor-Ligated cDNA Libraries: A Technique for Generating a cDNA Library for the Immediate Cloning of the 5′ Ends of mRNAs.Biotechniques15, 890-893 (1993).
Bea et al., Arginine-Rich Anti-Vascular Endothelial Growth Factor Peptides Inhibit Tumor Growth and Metastasis by Blocking Angiogenesis,J. Biol. Chem., 275:13588 (2000).
Baggio et al., Identification of epitope-like consensus motifs using mRNA display,J. Mol. Recognit., 15: 126-134 (2002).
Baron et al., Protein Modules,Elsevier Science Publishers Ltd.. (UK) , 13-17 (1991).
Baron et al., H NMR Assignment and Secondary Structure of the Cell Adhesion Type III Module of Fibronectin.Biochemistry31, 2068-2073 (1992).
Batori et al.,Protein Eng., Exploring the Potential of the Monobody Scaffold: Effects of Loop Elongation on the Stability of a Fibronectin Type III Domain, 15(12):1015-1020 (2002).
Bianchi et al., High Level Expression and Rational Mutagenesis of a Designed Protein, the Minibody.J. Mol. Biol.236, 649-659 (1994).
Boder et al., Yeast Surface Display for Screening Combinatorial Polypeptide Libraries.Nat. Biotech.15, 553-557 (1997).
Boldicke et al., Anti-VEGFR-2 scFvs for Cell Isolation. Single-Chain Antibodies Recognizing the Human Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2/flk-1) on the Surface of Primary Endothelial Cells and Preselected CD34+Cells from Cord Blood.,Stem Cells, 19(1):224-36 (2001).
Bork and Doolittle, Proposed Acquisition of an Animal Protein Domain by Bacteria.PNAS89, 8990-94 (1992).
Bork et al., The Immunoglobulin Fold Structural Classification, Sequence Patterns and Common Core,J. Mol. Biol., 242(4):309-320 (1994).
Brock, K. et al., Nucleotide sequencing of 5′ and 3′ termini of bovine viral diarrhea virus by RNA ligation and PCR,J. Virol. Methods38, 39-46 (1992).
Bruzik, J. et al., “Spliced leader RNAs from lower eukaryotes are trans-spliced in mammalian cells,”Nature360, 692-695 (1992).
Campbell & Spitzfaden, Building Proteins with Fibronectin Type III Modules,Structure, 2(5):333-337 (1994).
Clackson and Wells, In Vitro Selection from Protein and Peptide Libraries.TIB Tech12, 173-184 (1994).
Clackson et al,, Making Antibody Fragments Using Phage Display Libraries.Nature352, 624-628 (1991).
Claffey et al., Vascular Endothelial Growth Factor,J. Biol. Chem., 267:16317-16322 (1992).
Clarke et al., Folding and Stability of a Fibronectin Type III Domain of Human Tenascin.J. Mol. Biol.270, 771-778 (1997).
Copie et al., Solution Structure and Dynamics of Linked Cell Attachment Modules of Mouse Fibronectin Containing the RGD and Synergy Regions: Comparison with the Human Fibronectin Crystal Structure.J. Mol. Biol.277, 663-682 (1998).
Cota et al., Two Proteins with the Same Structure Respond Very Differently to Mutation: The Role of Plasticity in Protein Stability.J. Mol. Biol.302, 713-725 (2000).
Cujec et al., Seclection of v-Abl Tyrosine Kinase Substrate Sequences from Randomized Peptide and Cellular Proteomic Libraries Using mRNA Display,Chemistry&Biology9, 253-264 (2002).
DGENE Search Results (pp. 1-33) STN search results.
Dickinson et al., Crystal Structure of the Tenth Type III Cell Adhesion Module of Human Fibronectin.J. Mol. Biol.236, 1079-1092 (1994).
Dickinson et al., Crystals of the Cell-Binding Module of Fibronectin Obtained from a Series of Recombinant Fragments Differing in Length.J. Mol. Biol.238, 123-127 (1994).
Ely et al., Common Molecular Scaffold for two Unrelated RGD Molecules.Prot. Eng.8, 823-827 (1995).
Ferguson, K. et al., The SL1 trans-spliced leader RNA performs an essential embryonic function in Caenorhabditis elegans that can also be supplied by SL2 RNA.,Genes Dev.10, 1543-1556 (1996).
Ghosh et al., Structure of NF-KB p50 Homodimer Bound to a kB Site.Nature373, 303-310 (1995).
Grant et al., Structural Requirements for Biological Activity of the Ninth and Tenth Fill Domains, of Human Fibronectin.J. Biol. Chem.272, 6159-6166 (1997).
Hamers-Casterman et al., Naturally Occurring Antibodies Devoid of Light Chains.Nature363, 446-448 (1993).
Hammond et al., In Vitro Selection and Characterization of Bcl-XL-binding Proteins from a Mix of Tissue-Specific mRNA Display Libraries,The Journal of Biological Chemestry, vol. 276, No. 24, 2898-20898-20906 (2001).
Harpaz & Chothia, Many of the Immunoglobulin Superfamily Domains in Cell Adh
Chen Yan
Getmanova Elena
Gokemeijer Jochem
Harris Alan S.
Lim Ai Ching
Bristol--Myers Squibb Company
Bunner Bridget E
Howard Zachary C
Ropes & Gray LLP
LandOfFree
Pharmacokinetic modulation and compositions for modified FN3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmacokinetic modulation and compositions for modified FN3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacokinetic modulation and compositions for modified FN3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221433